

Newsletter

Lund 05 Jan 2021

Scandinavian ChemoTech enters into an agreement with Erik Penser Bank to monitor the company in the form of assignment analyses

Scandinavian ChemoTech AB (publ) has entered into an agreement with Erik Penser Bank AB to receive the service, *Penser Access*, where written analysis reports are the central part of the service.

The purpose of the agreement is to carry out a number of analyses that will aim to increase the stock market's knowledge of the company and provide indications of target prices.

"It feels good that ChemoTech is now deepening its collaboration with Erik Penser Bank and will be giving the stock market access to analyses and descriptions of the company's potential, developed by well-experienced analysts." - says Mohan Frick, CEO

For further information please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00,

E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se